Online Educational Activity

Managing Type 2 Diabetes: Perspectives on Evolving Treatment Standards and Gaps in Care On-Demand Webinar

Needs Statement/Intended Audience

This activity has been planned in accordance with the need to provide endocrinologists and other diabetes care providers with an update on the state of glycemic control, the impact of intensive therapy, and the latest findings in incretin therapy.

Educational Activity Learning Objectives

Upon completion of this course, the participants should be able to:

• Design type 2 diabetes treatment plans based on an understanding of the role of various therapies in precisely targeting pathophysiologic mechanisms of type 2 diabetes
• Define the impact of meeting glycemic goals on reducing the risk of microvascular and macrovascular complications in patients with type 2 diabetes
• Identify the major benefits and barriers of mono- and combination therapies used to assist patients in achieving glycemic control
• Understand the current findings on therapies targeting incretin modulation and put these findings into the larger perspective of natural progression of type 2 diabetes

Credit Statement

The France Foundation designates this educational activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Faculty

Pathophysiology of Type 2 Diabetes: What Have We Learned About Gaps in Meeting Glycemic Goals?
Ralph A. DeFronzo, MD
University of Texas Health Science Center

A Look at the Impact of Intensive Therapy on Microvascular and Macrovascular Complications
William T. Cefalu, MD
Pennington Biomedical Research Center

Incretin Modulatory Therapies: The Latest Clinical Findings
Lawrence Blonde, MD, FACP, FACE (Chairperson)
Ochsner Medical Center

Commercial Support Acknowledgment

This activity is supported by an independent medical education grant from the Bristol-Myers Squibb and AstraZeneca Pharmaceuticals LP, Alliance Partners.